Bicycle therapeutics announces publication of article highlighting preclinical data from bt7480 program in the journal of medicinal chemistry

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that an article highlighting preclinical data from bt7480, a bicycle tumor-targeted immune cell agonist® (bicycle tica™) targeting nectin-4 and agonizing cd137 (4-1bb), was published in the journal of medicinal chemistry. the article, titled “discov
BCYC Ratings Summary
BCYC Quant Ranking